Ultragenyx Pharmaceutical Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
On September 9, 2024, Michael Narachi, amember of the Company’s Board of Directors, adopted a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c), to sell up to 16,250 shares of the Company’s common stock, all of which shares are to be acquired upon the exercise of employee stock options, through June 17, 2025, subject to certain conditions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.